BriaCell Therapeutics (BCT.TO) has added NYU Langone Health's Laura and Isaac Perlmutter Cancer Center, as a clinical trial site in its ongoing Phase 3 clinical study, the company said on Thursday.
The Phase 3 clinical study in advanced breast cancer (Bria-ABC) is evaluating the company's lead clinical candidate, Bria-IMT, plus an immune check point inhibitor in advanced metastatic breast cancer.
Interim analysis of the Phase 3 study will be conducted after 144 patient events (deaths) have occurred, with overall survival (OS) as the primary endpoint.
The Bria-IMT combination regimen has also been granted FDA Fast Track designation.
BriaCell shares were last seen up US$0.033, to US$4.183, in U.S. pre-market trading.